Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 14th, 2020

Sunday’s Late-Breaking Science

These two Late-Breaking Science sessions are being presented today. The titles and individual links to the sessions are provided. Additionally, links are included for the two Meet the Trialist sessions taking place today.


Getty Images 1173258771

Sunday, Nov. 15

9-10 a.m. CST
LBS.04: Fish Oil, Fancy Drugs and Frustrations in Lipid Management

  • STRENGTH Trial: Cardiovascular Outcomes With Omega-3 Carboxylic Acids (Epanova) in Patients With High Vascular Risk and Atherogenic Dyslipidemia — STRENGTH
  • Effects of N-3 Fatty Acid Supplements on Clinical Outcome After Myocardial Infarction in the Elderly: Results of the Omemi Trial — OMEMI
  • A Three-Arm N-of-1 Trial With Statin, Placebo and Tablet Free Periods, to Verify Side Effects and Identify Their Cause: The SAMSON Trial — SAMSON
  • The Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia

                      4-4:45 p.m. CST

                      MT.04: Meet the Trialists #4

                      MT.05: Meet the Trialists #5

                      Meet the Trialist made possible in part from support of Amgen and Cytokinetics.

                      7:15-8:30 p.m. CST

                      LBS.05: Stents, Valves and Clots Daily Recap & Late-Breaking Science: Stents, Valves and Clots

                      • A Prospective Multicenter Randomized Controlled Trial Assessing the Safety and Efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System in Patients With Stable or Non-ST Elevation Acute Coronary Syndromes: Primary Endpoint Results of the PIONEER III Trial — PIONEER III
                      • One-Month Dual Antipletelet Therapy Followed by Aspirin Monotherapy After Drug Eluting Stent Implantation — One-Month DAPT trial


                      Interesting Stories
                      MiCare Path joins the AHA CHTI and will integrate AHA science-based
                      Sponsored by MiCare Path
                      MiCare Path joins the AHA CHTI and will integrate AHA science-based
                      Modern Wearable Defibrillation
                      Sponsored by Kestra Medical Technologies
                      Modern Wearable Defibrillation
                      New Double Take Videos from NEJM
                      Sponsored by NEJM Group
                      New Double Take Videos from NEJM
                      Data-driven precision medicine
                      Sponsored by Tempus
                      Data-driven precision medicine
                      More Content
                      audience
                      AHA22
                      Early ablation bests medication in treatment naïve AFib patients
                      Nov 9th, 2022
                      audience shot
                      AHA22
                      First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension
                      Nov 9th, 2022
                      audience shot
                      AHA22
                      Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
                      Nov 8th, 2022
                      LBS 05 panelists
                      AHA22
                      Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression
                      Nov 8th, 2022
                      audience shot
                      AHA22
                      Bivalirudin superior to unfractionated heparin in primary PCI following STEMI
                      Nov 8th, 2022
                      Panelists of the Mindful Disruption panel
                      Late-Breaking Science
                      Overcoming health disparities, health care advocates and mindfulness can better manage BP and CVD
                      Nov 7th, 2022
                      Person putting on tennis shows
                      AHA22
                      Join the Wellness Challenge at #AHA22
                      Oct 26th, 2022
                      Scientific Sessions attendees in lobby
                      Home
                      Join us for Scientific Sessions 2022 in Chicago or online
                      Sep 20th, 2022
                      Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
                      AHA21
                      Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
                      Nov 19th, 2021
                      Lbs02 Group Blood Patel
                      AHA21
                      Update on local and global hypertension science
                      Nov 19th, 2021
                      (from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
                      AHA21
                      Late-Breaking Science: New information in cardiac disease
                      Nov 15th, 2021
                      (from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA
                      AHA21
                      The latest science in heart failure
                      Nov 15th, 2021